Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

AMGN

Amgen

NASDAQ

Real-time Quotes | Nasdaq Last Sale

251.96

+1.65

+0.66%

Opening 15:40 05/14 EDT

OPEN

253.28

PREV CLOSE

250.31

HIGH

254.59

LOW

251.16

VOLUME

1.49M

TURNOVER

52 WEEK HIGH

276.69

52 WEEK LOW

210.28

MARKET CAP

144.76B

P/E (TTM)

20.87

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)

Benzinga · 7h ago

Amgen Inc. stock rises Thursday, still underperforms market

Shares of Amgen Inc. inched 0.49% higher to $252.07 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

marketwatch.com · 23h ago

Insights on the Recombinant DNA Technology Global Market to 2027 - Featuring Amgen, Bamboo Therapeutics and Biocon Among Others

, /PRNewswire/ -- The report has been added to offering.

PR Newswire - PRF · 23h ago

Swaine & Leidel Wealth Services, LLC Buys AvalonBay Communities Inc, Nasdaq Inc, iShares ...

GuruFocus News · 1d ago

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

Zacks · 1d ago

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

, /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secondary endpoin...

PR Newswire - PRF · 1d ago

Universal PropTech Confirms Launch of ISBRG Corp's SpotLight-19(C) Clinical Trial and New R&D Funding Assistance

Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - Universal PropTech Inc. (TSXV: UPI) (OTCQB: UPIPF) (FSE: 8LH) ("" or the "") is pleased to announce that ISBRG Corp., in which UPI owns a minority interest (see press release dated February 18, 2021), ann...

Newsfile Corp · 1d ago

Grimes & Company, Inc. Buys Costco Wholesale Corp, PerkinElmer Inc, Consumer Discretionary ...

GuruFocus News · 1d ago

Forecast

Actual (USD)

Estimate (USD)

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 30 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AMGN stock price target is 255.42 with a high estimate of 298.00 and a low estimate of 185.00.

EPS

Institutional Holdings

Institutions: 2.75K

Institutional Holdings: 464.07M

% Owned: 80.77%

Shares Outstanding: 574.55M

TypeInstitutionsShares

Increased

882

12.31M

New

238

3.07M

Decreased

756

21.21M

Sold Out

128

1.47M

Performance
Asset Allocation
Dividend History

No Data

Industry

Pharmaceuticals

+0.52%

Pharmaceuticals & Medical Research

+1.23%

Key Executives

Chairman/Chief Executive Officer/President/Director

Robert Bradway

Chief Financial Officer/Executive Vice President

Peter Griffith

Executive Vice President/General Counsel/Secretary

Jonathan Graham

Executive Vice President/Director of Human Resources

Lori Johnston

Executive Vice President

Murdo Gordon

Executive Vice President

David Reese

Executive Vice President

Esteban Santos

Senior Vice President

David Piacquad

Lead Director/Independent Director

Robert Eckert

Independent Director

Wanda Austin

Chief Accounting Officer/Vice President - Finance

Linda Louie

Independent Director

Brian Druker

Independent Director

Gregory Garland

Independent Director

Fred Hassan

Independent Director

Charles Holley

Independent Director

Tyler Jacks

Independent Director

Ellen Kullman

Independent Director

Amy Miles

Independent Director

Ronald Sugar

Independent Director

Robert Williams

Independent Director

R. Sanders Williams

Declaration Date Dividend Per Share Ex-Div Date: 03/03/2021
Dividend USD 1.76
05/14/2021; 12/16/2020
Dividend USD 1.76
02/11/2021; 10/21/2020
Dividend USD 1.6
11/13/2020; 07/23/2020
Dividend USD 1.6
08/14/2020; 03/04/2020
Dividend USD 1.6
05/15/2020; 12/11/2019
Dividend USD 1.6
02/13/2020; 10/22/2019
Dividend USD 1.45
11/14/2019; 08/02/2019
Dividend USD 1.45
08/14/2019; 03/07/2019
Dividend USD 1.45
05/16/2019; 12/07/2018
Dividend USD 1.45
02/14/2019; 10/23/2018
Dividend USD 1.32
11/15/2018; 07/31/2018
Dividend USD 1.32
08/16/2018; 03/07/2018
Dividend USD 1.32
05/16/2018; 12/12/2017
Dividend USD 1.32
02/14/2018; 10/24/2017
Dividend USD 1.15
11/16/2017; 07/28/2017
Dividend USD 1.15
08/15/2017; 03/07/2017
Dividend USD 1.15
05/15/2017; 12/20/2016
Dividend USD 1.15
02/13/2017; 10/14/2016
Dividend USD 1
11/14/2016; 07/22/2016
Dividend USD 1
08/15/2016; 03/02/2016
Dividend USD 1
05/13/2016; 12/15/2015
Dividend USD 1
02/11/2016; 10/14/2015
Dividend USD 0.79
11/12/2015; 07/28/2015
Dividend USD 0.79
08/13/2015; 03/04/2015
Dividend USD 0.79
05/12/2015; 12/17/2014
Dividend USD 0.79
02/10/2015; 10/17/2014
Dividend USD 0.61
11/10/2014; 07/25/2014
Dividend USD 0.61
08/12/2014; 03/05/2014
Dividend USD 0.61
05/13/2014; 12/13/2013
Dividend USD 0.61
02/11/2014; 10/16/2013
Dividend USD 0.47
11/12/2013; 07/26/2013
Dividend USD 0.47
08/14/2013; 03/06/2013
Dividend USD 0.47
05/14/2013; 12/13/2012
Dividend USD 0.47
02/11/2013; 10/10/2012
Dividend USD 0.36
11/13/2012; 07/19/2012
Dividend USD 0.36
08/14/2012; 03/15/2012
Dividend USD 0.36
05/14/2012; 12/15/2011
Dividend USD 0.36
02/13/2012; 10/13/2011
Dividend USD 0.28
11/15/2011; 07/28/2011
Dividend USD 0.28
08/16/2011

All
Financials
Insiders

About AMGN

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.